Strand Therapeutics picks up $52m Series A

Strand Therapeutics, a developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, has raised $52 million in Series A financing.

25 June 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles